Contraceptive Technology Update – January 1, 2011
January 1, 2011
View Issues
-
New year, new oral contraceptives: 2 new OCs join birth control options
Add Beyaz and Lo Loestrin Fe to the list of birth control choices for U.S. women. Both oral contraceptives (OCs) received Food and Drug Administration (FDA) approval in late 2010. -
What are the top myths about pills?
Your next patient tells you she would like to use oral contraceptives (OCs) for birth control, but she says a family member told her using pills would affect her long-term fertility. What information do you provide her regarding OCs? -
Tenofovir gel makes strides in development
Microbicide research is moving forward with two new developments: the Food and Drug Administration (FDA) has granted Fast Track approval designation for 1% tenofovir gel, which will facilitate the development and expedite the review of the drug. -
More data emerge from Women's Health Initiative
Results from a long-term follow-up analysis of participants in the Women's Health Initiative (WHI) suggest that among postmenopausal women, use of estrogen plus progestin is associated with an increased incidence of breast cancers that are more advanced, and with a higher risk of deaths attributable to breast cancer. -
Ask The Experts: What's the evidence for using two condoms?
Question: What is the evidence that two condoms may be used at once? Who does this? What are their reasons for doing this? What are the other things that can do done to prevent condom breakage? -
Washington Watch: Women begin to see impact of health reform
The end of September, marking six months after President Obama signed into law the Patient Protection and Affordable Care Act, was the effective date for numerous provisions intended to expand patients' rights and coverage under private insurance. -
2010 Salary Survey Results: Family planners hold the line on salaries, jobs — Keep an eye on legislation, economy in coming year
In a year when belt-tightening seemed to be a national pastime, about 35% of participants in the Contraceptive Technology Update Salary Survey reported a 1-3% uptick in salary, with 43% seeing no change in pay levels.